Renal Cell Carcinoma
Pipeline by Development Stage
Drug Modality Breakdown
Renal Cell Carcinoma is a $2.1B indication-attributable market with mature but consolidating competition dominated by tyrosine kinase inhibitors.
Key Trends
- CABOMETYX (cabozantinib) and LENVIMA (lenvatinib) command ~60% of market share, establishing duopoly dynamics
- Receptor tyrosine kinase inhibitors represent 87% of spending; emerging HIF-2α inhibitors (WELIREG) signal mechanism diversification
- Two major patent cliffs approaching (AFINITOR in 2028, NEXAVAR in 2028) create near-term generic erosion pressure
Career Verdict
RCC is a stable, well-funded oncology niche with strong job availability, but limited growth upside—best for specialists seeking established commercial infrastructure rather than early-stage innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | CABOMETYX (cabozantinib) | Exelixis | $1.1B | 52% | Peak | Stable | 7.2yr |
| 2 | LENVIMA (lenvatinib) | Eisai | $779M | 37% | Peak | Stable | 12.5yr |
| 3 | INLYTA (axitinib) | Pfizer | $467M | 22% | Peak | Declining | 11.2yr |
| 4 | FOTIVDA (tivozanib) | $102M | 5% | Peak | Stable | 13.5yr | |
| 5 | VOTRIENT (pazopanib) | Novartis | $98M | 5% | LOE_Approaching | Declining |
Drug Class Breakdown
market standard, stable dominance
competitive consolidation
emerging mechanism, limited traction
legacy positioning, declining
Career Outlook
StableRCC is a defensible, cash-flowing oncology niche with established patient populations and proven efficacy standards, but limited innovation upside and incremental competitive dynamics. The duopoly of CABOMETYX and LENVIMA creates job security for sales, medical affairs, and field-based roles but restricts breakthrough opportunities. Patent cliffs 2028–2032 will trigger generic erosion and potential restructuring, particularly at Novartis and Bayer, but market consolidation is unlikely to eliminate core commercial teams.
Breaking In
Enter RCC as a commercial generalist or clinical operations specialist if you seek stable employment with established playbooks; avoid if you want to pioneer early-stage mechanisms or work on first-in-class assets.
For Experienced Professionals
Leverage RCC expertise to pivot into high-growth IO-oncology or rare kidney cancer sub-segments (VHL loss, papillary variants); consider early career transitions before 2028 patent cliffs create competitive compensation pressure.
In-Demand Skills
Best For
Hiring Landscape
RCC-focused hiring is modest (6,668 jobs across 9 companies) but concentrated in Commercial (1,233 roles, $266K avg) and Manufacturing (580 roles, $112K avg), reflecting mature market dynamics. Pfizer, Novartis, and Merck dominate RCC-specific talent acquisition, though broader pharma hiring (Abbott, Takeda, Amgen) dwarfs RCC-only recruitment. Geographic and functional specialization creates stable but narrower career pathways than growth oncology segments.
By Department
RCC hiring skews commercial and manufacturing, reflecting market maturity; R&D roles ($224K avg) are rare, limiting high-growth career acceleration compared to emerging oncology areas.
On Market (5)
Approved therapies currently available
Competitive Landscape
47 companies ranked by most advanced pipeline stage
+17 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 12,386 patients across 50 trials
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
High Dose IL 2 and Entinostat in RCC
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Neoadjuvant Pazopanib in Renal Cell Carcinoma
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Efficacy of Ultrasound Contrast Agent to Assess Renal Masses
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Related Jobs in Oncology
Field Medical Manager, Oncology
Senior Healthcare Representative, Oncology & Hematology (mazowieckie, podlaskie)
Country Portfolio Lead, Oncology
Postdoctoral Research Fellow - Agentic AI for Spatial Modeling of Disease Microenvironments
Chef – Étiquetage à l’échelle mondiale // Global Labeling Lead, Manager
Senior Oncology Account Specialist Hematology Minneapolis N, MN
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.